In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 425-432

  White, H Steve ^a   McCabe, R Tyler ^b   Armstrong, Heather ^a   Donevan, Sean D ^a   Cruz, Lourdes J ^a,c   Abogadie, Fe C ^a   Torres, Josep ^d   Rivier, Jean E ^d   Paarmann, Ingo ^e   Hollmann, Michael ^e   Olivera, Baldomero M ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Cognetix Inc ^*  (United States)

^c University of the Philippines Diliman   (Philippines)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; CONANTOKIN R; DIZOCILPINE; GLYCINE; IFENPRODIL; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PENTETRAZOLE; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DRUG ISOLATION; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; FEMALE; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SNAIL; XENOPUS;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CEREBRAL CORTEX; CONOTOXINS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROSHOCK; EVOKED POTENTIALS; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; KAINIC ACID; MALE; MICE; MOLLUSK VENOMS; OOCYTES; PENTYLENETETRAZOLE; PIPERIDINES; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; SEIZURES; SOUND; XENOPUS;

EID: 0033976427     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Behr J, Lysonn KJ and Mody I (1998) Enhanced propagation of epileptiform activity through the kindled dentate gyrus. J Neurophysiol 79:1727-1732.
2. Brusa R, Zimmermann F, Koh DS, Feldmeyer D, Gass P, Seeburg PH and Sprengel R (1995) Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science (Wash DC) 270:1677-1680.
3. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA and Monaghan DT (1994) The molecular basis of NMDA receptor subtypes: Native receptor diversity is predicted by subunit composition. J Neurosci 14:5471-5484.
4. Chapman AG (1998) Glutamate receptors in epilepsy. Prog Brain Res 116:371-383.
5. Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, Schmidt AW and Fox CB (1991) Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 34:3085-3090.
6. 2+ channels in rat and mouse cultured hippocampal pyramidal neurons. Br J Pharmacol 116:2801-2810.
7. Dichter MA (1994) Emerging insights into mechanisms of epilepsy: implications for new antiepileptic drug development. Epilepsia 35:S51.
8. Finney DJ (1971) Probit Analysis, Cambridge University Press, London.
9. Fisher RS, Cysyk BJ, Lesser RP, Pontecorvo MJ, Ferkany JT, Schwerdt PR, Hart J and Gordon B (1990) Dextromethorphan for treatment of complex partial seizures. Neurology 40:547-549.
10. Haack JA, Parks TN and Olivera BM (1993) Conantokin-G antagonism of the NMDA receptor subtype expressed in cultured cerebellar granule cells. Neurosci Lett 163:63-66.
11. Hamill OP, Marty A, Neher E, Sakmann B and Sigworth F (1981) Improved patch clamp technique for high resolution current recording from cells and cell free membrane patches. Pfluegers Arch 391:85-100.
12. Hammerland LG, Olivera BM and Yoshikami D (1992) Conantokin-G selectively inhibits N-methyl-D-aspartate-induced currents in Xenopus oocytes injected with mouse brain mRNA. Eur J Pharmacol 226:239-244.
13. Hertz E, Yu ACH, Hertz L, Juurlink BHJ and Schousboe A (1990) Preparation of primary cultures of mouse cortical neurons, in A Dissection and Tissue Culture Manual of the Nervous System (Shahar A, Devillis J, Vernadakis A and Haber B eds) pp 183-186, Alan R. Liss, New York.
14. Hollmann M and Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31-108.
15. 3H] (+)-3-PPP-labeled sigma binding sites in guinea pig brain membranes. Eur J Pharmacol 176:247-248.
16. Laurie DJ and Seeburg PH (1994) Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur J Pharmacol 268:335-345.
17. Loscher W and Schmidt D (1994) Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation? Epilepsy Res 17:95-134.
18. Mathern GW, Pretorius JK, Leite JP, Kornblum HI, Mendoza D, Lozada A and Bertram III EH (1998) Hippocampal AMPA and NMDA mRNA levels and subunit immunoreactivity in human temporal lobe epilepsy patients and a rodent model of chronic mesial limbic epilepsy. Epilepsy Res 32:154-171.
19. McCool BA and Lovinger DM (1995) Ifenprodil inhibition of the 5-hydroxytryptamine3 receptor. Neuropharmacology 34:621-629.
20. McIntosh M, Cruz LJ, Hunkapiller MW, Gray WR and Olivera BM (1982) Isolation and structure of a peptide toxin from the marine snail Conus magus. Arch Biochem Biophys 218:329-334.
21. McNamara JO (1994) Cellular and molecular basis of epilepsy. J Neurosci 14:3413-3425.
22. Meldrum BS (1994) The role of glutamate in epilepsy and other CNS disorders. Neurology 44:S14-S23.
23. Meldrum BS (1995) Neurotransmission in epilepsy. Epilepsia 36:S30-S35.
24. Monaghan DT and Larsen H (1997) NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. J Pharmacol Exp Ther 280:614-620.
25. ++ entry into neurons. J Toxicol-Toxin Rev 9:179-202.
26. Olivera BM (1997) E. E. Just Lecture 1996. Conus venom peptides, receptor and ion channel targets and drug design: 50 million years of neuropharmacology. Mol Biol Cell 8:2101-2109.
27. Pellegrini-Giampietro DE, Zukin RS, Bennett MVL, Cho SH and Pulsinelli WA (1992) Switch in glutamate receptor subunit gene expression in CAl subfield of hippocampus following global ischemia in rats. Proc Natl Acad Sci USA 89:10499-10503.
28. Priestly T, Laughton P, Myers J, Le Bourdelles B, Kerby J and Whiting PJ (1995) Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol Pharmacol 48:841-848.
29. Skeen GA, White HS and Twyman RE (1994) The dihydropyridine nitrendipine reduces N-methyl-D-aspartate (NMDA)-evoked currents of rodent cortical neurons through a direct interaction with the NMDA receptor-associated ion channel. J Pharmacol Exp Ther 271:30-38.
30. Sveinbjornsdottir S, Sander JWAS, Upton D, Thompson PJ, Patsalos PN, Hirt D, Emre M, Lowe D and Duncan JS (1993) The excitatory amino acid antagonist DCPP-ene (SDZEAA-494) in patients with epilepsy. Epilepsy Res 16:165-174.
31. Troupin AS, Mendius JR, Cheng F and Risinger MW (1986) MK-801, in New Anticonvulsant Drugs: Current Problems in Epilepsy (Meldrum BS and Porter RJ eds) pp 191-201, John Libbey, London.
32. White HS, Patel S and Meldrum BS (1992) Anticonvulsant profile of MDL 27,266: an orally active, broad-spectrum anticonvulsant agent. Epilepsy Res 12:217-226.
33. White HS, Wolf HH, Woodhead JH and Kupferberg HJ (1998) The National Institutes of Health Anticonvulsant Drug Development Program: Screening for efficacy. Adv Neurol 76:29-39.
34. White HS, Woodhead JH, Franklin MR, Swinyard EA and Wolf HH (1995) General principles: Experimental selection, quantification, and evaluation of antiepileptic drugs, in Antiepileptic Drugs, 4th ed (Levy RH, Mattson RH and Meldrum BS eds) pp 99-110, Raven Press, New York.
35. Williams K ( 1993) Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44:851-859.
36. Woodbury LA and Davenport VD (1952) Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern. Arch Int Pharmacodyn Ther 92:97-104.